Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29883021 | 0.98 | DRD2 (0.54) | DRD2DRD3ALDH1A1ADRB1HTR3E | |
| Hydrochloric Acid SCHEMBL23302481 | 0.98 | DRD2 (0.54) | DRD2DRD3ALDH1A1ADRB1HTR3E | |
| SCHEMBL24990144 | 0.88 | PIM1 (0.50) | DRD2DRD3ALDH1A1PIM1CDK9 | |
| SCHEMBL2927680 | 0.87 | DRD2 (0.55) | DRD2DRD3ALDH1A1ADRB1HTR3E | |
| Hydrochloric Acid SCHEMBL20139208 | 0.86 | DRD2 (0.54) | DRD2DRD3ALDH1A1ADRB1HTR3E | |
| SCHEMBL30895187 | 0.85 | CYP11B1 (0.51) | KDM4ETP53TRPV4PARP1TNK2 | |
| SCHEMBL2709917 | 0.85 | DRD2 (0.60) | DRD2DRD3ALDH1A1ADRB1HTR3E | |
| SCHEMBL15976200 | 0.83 | CYP11B1 (0.50) | ALDH1A1KDM4ETP53TRPV4PARP1 | |
| SCHEMBL142269 | 0.83 | CYP11B1 (0.50) | ALDH1A1KDM4ETP53TRPV4PARP1 | |
| SCHEMBL24990170 | 0.81 | ADRB1 (0.65) | DRD2DRD3ADRB1HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4534533-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-118076597-A | Azaquinolinone derivative, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023232069-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023011596-A1 | AMIDE COMPOUND AND USE THEREOF | 中国药科大学 | 2023-02-09 | — | — | WO | disclosed |
| CN-114929673-A | Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient | 多临生物株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021086077-A1 | ISOQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION, COMPRISING SAME AS ACTIVE INGREDIENT, FOR PREVENTION OR TREATMENT OF POLY(ADP-RIBOSE)POLYMERASE-1 (PARP-1)-ASSOCIATED DISEASE | 충남대학교 산학협력단 | 2021-05-06 | — | — | WO | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013830-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| US-7754719-B2 | Substituted piperidine derivatives as somatostatin SST1 receptor antagonists | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-6664258-B1 | Transphenylpiperazines; central dopaminergic activity | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-6372762-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | FLIRI ANTON FRANZ JOSEPH (US) | 2002-02-14 | — | — | US | disclosed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0925291-A1 | SPIROCYCLIC DOPAMINE RECEPTOR SUBTYPE LIGANDS | PFIZER INC. (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998008835-A1 | SPIROCYCLIC DOPAMINE RECEPTOR SUBTYPE LIGANDS | PFIZER INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | OPRK1, OPRD1, MC2R | DRD2 45/4885DRD3 9/4885ALDH1A1 396/4885 |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | DRD2 126/4885DRD3 457/4885ALDH1A1 395/4885 |
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | DRD2 4074/4885DRD3 4090/4885ALDH1A1 4630/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | DRD2 108/4885DRD3 143/4885ALDH1A1 591/4885 |
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | PARP1, PARP8, PARP11 | DRD2 4067/4885DRD3 4654/4885ALDH1A1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.